This past spring brought several updates to the renewable energy tax credit guidance from the Inflation Reduction Act, prompting those in the space to review their options for tax liability insurance.
High-impact drugs represent proportionately low utilization compared to opioids or NSAIDs, but they can increase pharmacy spend exponentially on impacted claims.
Discover what’s in store for utilization review—everything from compliance with state regulations to adapting to new care models for mental health to the promise of AI-driven processes.
Insureds want fee transparency. The right TPA partner will communicate effectively, demonstrate where there are savings and work to build tailored solutions.
CorVel has witnessed topical costs rise following the recent drop in opioid prescriptions, and now offers alternatives to manage their expense without impacting care.
Data, AI and point-of-care screening devices are revolutionizing the musculoskeletal health care field, giving providers and patients a real-time understanding of recovery and the solutions that can drive success.